Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts. Show more

Location: 1601 Trapelo Road, Waltham, MA, 02451, United States | Website: https://invivyd.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

217.8M

52 Wk Range

$0.35 - $2.74

Previous Close

$1.04

Open

$1.03

Volume

3,301,668

Day Range

$0.96 - $1.04

Enterprise Value

184.8M

Cash

34.91M

Avg Qtr Burn

-28.28M

Insider Ownership

19.20%

Institutional Own.

49.16%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.